Skip to main content

Engineering a lung bacteria to treat idiopatic lung fibrosis and other non-infectious lung diseases

Project description

Engineering a lung mycobacterium as a vector for the treatment of idiopathic pulmonary fibrosis

Dysregulation of immunomodulatory molecules plays an essential role in many pulmonary diseases, including infections, lung cancer and idiopathic pulmonary fibrosis (IPF). In the case of IPF, inflammation results in senescence of the alveolar cells with telomere shortening and dysregulation of miRNAs. Modulating the immune response could provide a treatment for lung diseases. The EU-funded LUNG BIOREPAIR project aims to engineer the Mycovector, the genome-reduced lung bacterium Mycoplasma pneumoniae, as a vector to deliver protein-RNA complexes and express immunomodulatory proteins in alveolar cells. The project will use the non-pathogenic engineered version of Mycovector expressing different combinations of active biomolecules to treat bleomycin induced IPF in mice.

Host institution

FUNDACIO CENTRE DE REGULACIO GENOMICA
Net EU contribution
€ 2 973 296,00
Address
Carrer Doctor Aiguader 88
08003 Barcelona
Spain

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Non-EU contribution
€ 0,00

Beneficiaries (1)

FUNDACIO CENTRE DE REGULACIO GENOMICA
Spain
Net EU contribution
€ 2 973 296,00
Address
Carrer Doctor Aiguader 88
08003 Barcelona

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Non-EU contribution
€ 0,00